Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
51 hedge funds and large institutions have $82.6M invested in Concert Pharmaceuticals, Inc. in 2014 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 11 increasing their positions, 17 reducing their positions, and 15 closing their positions.
42% more capital invested
Capital invested by funds: $58M → $82.6M (+$24.5M)
2% more funds holding
Funds holding: 50 → 51 (+1)
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
35% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$11.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.18M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.19M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$2.94M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$2.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$11.6M |
| 2 |
DM
Deerfield Management
New York
|
-$6.24M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.15M |
| 4 |
BG
BlackRock Group
London,
United Kingdom
|
-$1.05M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$705K |
CNCE Hedge Fund Activity: Q3 2014 in Review
51 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q3 2014, worth a combined $82.6M — up 42% from $58M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new CNCE positions and 15 closed out — a net gain of 1 holder — while 11 added to existing stakes and 17 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $11.7M. The largest seller was Bain Capital Public Equity Management, exiting entirely with an estimated $11.6M sold.
- 51 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q3 2014, up from 50 in Q2 2014.
- Funds reported $82.6M of Concert Pharmaceuticals, Inc. stock for Q3 2014, up 42% quarter-over-quarter.
- 16 funds opened new Concert Pharmaceuticals, Inc. positions in Q3 2014 and 15 closed out, a net change of +1 holder.
- The largest Concert Pharmaceuticals, Inc. buyer in Q3 2014 was BVF Inc, an estimated $11.7M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q3 2014 was Bain Capital Public Equity Management, an estimated $11.6M sold.
Based on aggregated 13F filings for Q3 2014.